Key result
A 79-year-old athletic man with long-standing atrial fibrillation has maintained an active lifestyle without stroke for 48 years on a regimen of digoxin and aspirin, despite modern guidelines.
Why the study?
Drug therapies for rate management and stroke prevention in AF have evolved over decades, but clinical application should consider quality of life and patient preferences.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case report highlights that patient preferences and quality of life considerations may sometimes lead to adherence to older, non-guideline-directed therapies (digoxin and aspirin) in long-standing atrial fibrillation with good clinical tolerance.
During the last several decades, there have been major advances in the evolution of drug therapies for the rate management of atrial fibrillation (AF). Initially, the drug of choice was digoxin but currently, the drug of choice is beta-adrenergic blockers. Drug therapies for stroke prevention in AF have also evolved. Initially, the drug of choice was aspirin, then became warfarin, and now in the current era, there are newer oral anticoagulants, such as apixaban, which are the preferred drugs. In this case report, we present the details of a 79-year-old athletic man who developed palpitations due to rapid AF at age 31. At the time of his initial presentation, he was treated with digoxin and aspirin and has remained on these drugs to the present. In 1973, 28 years after his initial presentation, he became the United Kingdom (UK) amateur tennis champion in the 55 and over division at age 59. At present, the clinical applications of advances in the management of AF should include quality of life considerations in the context of patient preferences. This patient is an active and vigorous 79-year-old man who plays competitive tennis and pickleball. He steadfastly adheres to an antediluvian regimen for the management of his AF, but this may be viewed in the context of the famous quotation by Bert Lance, Director of the Office of Management and Budget in the US under President Carter who said "sometimes, if it ain't broke, don't fix it." In addition to the evolution of drug therapies from digoxin to beta-adrenergic blockers for rate control as well as from aspirin to warfarin to apixaban for the prevention of stroke, there have been other recent remarkable advances. For example, recent promising findings from randomized trials include that early rhythm control was more effective than rate control as well as that cryoballoon ablation was superior to drug therapies. These findings require confirmation in additional randomized trials designed a priori to test these promising but unproven hypotheses.
No takes yet. Share an insight, caveat, or question.
Krishnaswamy et al. (2021) conducted a case report in Atrial Fibrillation (n=1). Digoxin and aspirin was evaluated. A 79-year-old athletic man with long-standing atrial fibrillation has maintained an active lifestyle without stroke for 48 years on a regimen of digoxin and aspirin, despite modern guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: